Blood uric acid, homocysteine, and IL-17 levels in people with lupus nephritis
Official title: Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Run by Sohag University · NCT07017868 · Data updated 2026-11-12
This research will test whether blood levels of uric acid, homocysteine, and interleukin‑17 are linked to kidney problems in adults with lupus.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | February 1, 2026 |
| Study ends | April 1, 2026 |
| Registry record updated | June 12, 2025 |
| Trial ID | NCT07017868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with SLE by SLICC criteria who can give informed consent and cooperate with visits, particularly those with suspected or confirmed lupus nephritis, are the intended participants.
✕Probably not a fit
People with other autoimmune diseases, pregnancy, diabetes, hypertension, heart or liver failure, chronic non‑lupus renal disease, or those on uric‑acid–lowering treatments may not benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, single-center study at Sohag University Hospital measuring serum uric acid, homocysteine, and IL-17 in adults with SLE and matched controls. Participants meet SLICC SLE criteria and are evaluated for lupus nephritis using clinical markers (proteinuria, active urinary sediment, serum creatinine) with renal biopsy data used when available. Blood samples will be analyzed and biomarker levels correlated with measures of renal involvement and disease activity. Key exclusions (other autoimmune disease, pregnancy, major comorbidities, or treatments affecting uric acid) are used to reduce confounding.
Why it matters
Potential benefit: If successful, this could identify simple blood markers to help detect or monitor kidney involvement in lupus and reduce reliance on invasive biopsies.
How similar studies have gone: Previous studies have reported elevated IL-17 and altered homocysteine and uric acid in SLE and lupus nephritis, but findings have been mixed and no definitive noninvasive biomarker has been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ● Aged ≥18 years. * SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls. * Patients cooperative and can answer questions. * Patients who are able and willing to give written informed consent Exclusion Criteria: * ● Individuals with other autoimmune diseases. * Patients receive any hyperuricemia treatment * Pregnancy * Malignancy * Diabetes. * Hypertension. * Heart failure. * Hepatic diseases. * Chronic renal failure other than lupus nephritis. * Renal artery stenosis. * Renal vein thrombosis. * Intrarenal arteriovenous fistula. * Obstructive nephropathy. * Urinary tract obstruction that could affect RI of intra renal arteries. * Uncooperative patients. * Patients not able and willing to give written informed consent.
Where it's running
-
Sohag university Hospital
Sohag, Egypt Recruiting
Study contacts
- Study coordinator: Sara M Ahmed, resident
- Email: sara_abdelrahim_post@med.sohag.edu.eg
- Phone: 01099676623
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.